JP2023549342A5 - - Google Patents
Info
- Publication number
- JP2023549342A5 JP2023549342A5 JP2023527473A JP2023527473A JP2023549342A5 JP 2023549342 A5 JP2023549342 A5 JP 2023549342A5 JP 2023527473 A JP2023527473 A JP 2023527473A JP 2023527473 A JP2023527473 A JP 2023527473A JP 2023549342 A5 JP2023549342 A5 JP 2023549342A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063110711P | 2020-11-06 | 2020-11-06 | |
| US63/110,711 | 2020-11-06 | ||
| PCT/US2021/058162 WO2022098936A1 (en) | 2020-11-06 | 2021-11-05 | Selecting neoantigens for personalized cancer vaccine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023549342A JP2023549342A (ja) | 2023-11-24 |
| JP2023549342A5 true JP2023549342A5 (https=) | 2024-11-12 |
| JPWO2022098936A5 JPWO2022098936A5 (https=) | 2024-11-12 |
Family
ID=78695860
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023527473A Pending JP2023549342A (ja) | 2020-11-06 | 2021-11-05 | 個別化されたがんワクチンのためのネオアンチゲンの選択 |
Country Status (5)
| Country | Link |
|---|---|
| US (1) | US20230197192A1 (https=) |
| EP (1) | EP4241274A1 (https=) |
| JP (1) | JP2023549342A (https=) |
| CN (1) | CN116802738A (https=) |
| WO (1) | WO2022098936A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP2024508677A (ja) * | 2021-02-05 | 2024-02-28 | アマゾン テクノロジーズ インコーポレイテッド | 個別化がんワクチン用ネオアンチゲンのランク付け |
| WO2025128926A1 (en) | 2023-12-13 | 2025-06-19 | Amazon Technologies, Inc. | Methods of identifying and treating individuals with elevated cancer risk |
| US20250197924A1 (en) | 2023-12-15 | 2025-06-19 | Amazon Technologies, Inc. | Methods for selection and combination of sequencing results from biological samples for neoantigen scoring |
| WO2026073127A1 (en) | 2024-09-30 | 2026-04-02 | Amazon Technologies, Inc. | Dual assay to boost accuracy of detected actionable variants in liquid biopsy |
| WO2026072916A1 (en) | 2024-09-30 | 2026-04-02 | Amazon Technologies, Inc. | Structural variant detection in circulating tumor dna |
Family Cites Families (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4235871A (en) | 1978-02-24 | 1980-11-25 | Papahadjopoulos Demetrios P | Method of encapsulating biologically active materials in lipid vesicles |
| US4722848A (en) | 1982-12-08 | 1988-02-02 | Health Research, Incorporated | Method for immunizing animals with synthetically modified vaccinia virus |
| US4501728A (en) | 1983-01-06 | 1985-02-26 | Technology Unlimited, Inc. | Masking of liposomes from RES recognition |
| US5019369A (en) | 1984-10-22 | 1991-05-28 | Vestar, Inc. | Method of targeting tumors in humans |
| US4837028A (en) | 1986-12-24 | 1989-06-06 | Liposome Technology, Inc. | Liposomes with enhanced circulation time |
| US5057540A (en) | 1987-05-29 | 1991-10-15 | Cambridge Biotech Corporation | Saponin adjuvant |
| US4912094B1 (en) | 1988-06-29 | 1994-02-15 | Ribi Immunochem Research Inc. | Modified lipopolysaccharides and process of preparation |
| US5703055A (en) | 1989-03-21 | 1997-12-30 | Wisconsin Alumni Research Foundation | Generation of antibodies through lipid mediated DNA delivery |
| US5204253A (en) | 1990-05-29 | 1993-04-20 | E. I. Du Pont De Nemours And Company | Method and apparatus for introducing biological substances into living cells |
| CA2646539A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Imidazoquinoxaline compounds as immunomodulators |
| CA2646891A1 (en) | 2006-03-23 | 2007-09-27 | Novartis Ag | Immunopotentiating compounds |
| KR20150093658A (ko) * | 2012-10-09 | 2015-08-18 | 파이브3 제노믹스, 엘엘씨 | 종양 클론형성능 분석을 위한 시스템 및 방법 |
| RU2729116C2 (ru) * | 2015-12-16 | 2020-08-04 | Гритстоун Онколоджи, Инк. | Идентификация, производство и применение неоантигенов |
| US10364468B2 (en) * | 2016-01-13 | 2019-07-30 | Seven Bridges Genomics Inc. | Systems and methods for analyzing circulating tumor DNA |
| EP3652318A1 (en) * | 2017-07-11 | 2020-05-20 | Actym Therapeutics, Inc. | Engineered immunostimulatory bacterial strains and uses thereof |
| JP7763588B2 (ja) * | 2017-09-05 | 2025-11-04 | グリットストーン バイオ インコーポレイテッド | Ｔ細胞療法用の新生抗原の特定法 |
| CN112771214B (zh) * | 2018-09-27 | 2025-06-13 | 耐考德治疗股份有限公司 | 用于选择新表位的方法 |
| AU2019404547B2 (en) * | 2018-12-21 | 2025-01-30 | Biontech Us Inc. | Method and systems for prediction of HLA class II-specific epitopes and characterization of CD4+ T cells |
-
2021
- 2021-11-05 US US17/616,145 patent/US20230197192A1/en active Pending
- 2021-11-05 JP JP2023527473A patent/JP2023549342A/ja active Pending
- 2021-11-05 EP EP21810856.1A patent/EP4241274A1/en active Pending
- 2021-11-05 WO PCT/US2021/058162 patent/WO2022098936A1/en not_active Ceased
- 2021-11-05 CN CN202180086487.8A patent/CN116802738A/zh active Pending